



► BIOPHARMA POOL

Rowena Choudrie
Kevin Zikaras

**ACTINIUM PHARMACEUTICALS ADDS TO
PRODUCT DEVELOPMENT AND CLINICAL
RESEARCH TEAMS**



Rowena Choudrie

Actinium Pharmaceuticals, a biopharmaceutical company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Rowena Choudrie to the position of senior director, pharmaceutical product development, and Kevin Zikaras to the position of senior clinical scientist.

Ms. Choudrie has more than 20 years of pharmaceutical industry experience with roles of increasing responsibility in product development. At Actinium, she is responsible for clinical trial material supply, drug product process scale-up to support commercial supply and final product formulation.

Mr. Zikaras joins Actinium from Bristol-Myers Squibb, where he was a clinical protocol manager in the immuno-oncology group since 2014.

Dr. Paul Kassner
Dr. David Wustrow

**FLX BIO HIRES SENIOR LEADERS IN
IMMUNO-ONCOLOGY DRUG DISCOVERY**



Dr. Paul Kassner

FLX Bio, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, has appointed Paul Kassner, Ph.D., as VP, quantitative biology, and David Wustrow, Ph.D., as VP, drug discovery.



Dr. David Wustrow

Dr. Kassner joined FLX Bio after 18 years of building and leading high-performance technical groups in various biopharmaceutical organizations. Most recently, he was director of research and head of the genome analysis unit at Amgen.

Before joining FLX Bio, Dr. Wustrow held the position of VP, chemical and pharmaceutical sciences at Cleve Biosciences.

Gary Zieziula
**EMD SERONO APPOINTS PRESIDENT AND
MANAGING DIRECTOR**

EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany, has appointed Gary Zieziula president and managing director, North America. In this role, he is re-



Gary Zieziula

sponsible for all areas of the company's business, including driving overall strategic direction and maximizing growth across the region. Mr. Zieziula joined EMD Serono in 2014 as chief commercial officer, responsible for the performance of the company's franchises in multiple sclerosis, fertility, endocrinology, and oncology.

EMD Serono is a leader in specialty care, integrating cutting-edge science, innovative medicines and devices, as well as industry-leading patient support and access programs.

► CRO POOL

Julie Ross
ADVANCED CLINICAL APPOINTS PRESIDENT



Julie Ross

Advanced Clinical, a clinical development organization, has promoted Julie Ross to president.

Ms. Ross' broadened span of responsibilities include leading all of the business lines within Advanced Clinical, inclusive of CRO, strategic talent acquisition, FSP, quality services, and computer systems validation.

She is on the board of directors for the Healthcare Businesswomen's Association.

► AGENCY POOL

Laurie Bartolomeo
Drew Desjardins
John Kemble
Dr. Dan Zaksas
DUDNYK MAKES PROMOTIONS



Laurie Bartolomeo



Drew Desjardins

Laurie Bartolomeo, Drew Desjardins, and John Kemble have been promoted from senior VPs at Dudnyk to executive VPs. In addition, Dan Zaksas, Ph.D., has been promoted to senior VP, director of medical and scientific affairs.

The collaboration between Ms. Bartolomeo, executive VP, creative director, and Mr. Kemble, executive VP, creative director, began in 2006 with Ms. Bartolomeo's return to Dudnyk after a four-year hiatus. Their early partnership produced



John Kemble



Dr. Dan Zaksas

award-winning work for many of Dudnyk's clients.

Mr. Desjardins, executive VP, chief strategy officer, joined the Dudnyk team in 2011 to provide strategy guidance to the agency's clients and business development activities.

Dr. Zaksas, senior VP, director of medical and scientific affairs, provides scientific guidance and medical strategy across the full spectrum of products and therapeutic areas at Dudnyk.

Doug Burcin
Leslie Jamison
Michael Young
KLICK HIRES THREE SENIOR EXECUTIVES



Doug Burcin



Leslie Jamison



Michael Young

Doug Burcin has joined Klick as chief growth officer. Leslie Jamison is Klick's new senior VP of brand strategy. And Michael Young is VP of strategy at Klick's Sensei Labs.


Mr. Burcin is focused on expanding Klick's capabilities. He joins Klick after spending 17 years at Havas Health, the last eight as global CEO.

Ms. Jamison brings more than 25 years of experience in brand strategy development, and customer insight-driven marketing to Klick.

Previously, she was managing director at in-sync, focused on healthcare.

Mr. Young was formerly VP, business development for Parexel International.

Tammy Fischer
**MCCANN HEALTH APPOINTS CHIEF GROWTH
OFFICER FOR NORTH AMERICA**



Tammy Fischer

McCann Health has appointed Tammy Fischer to the new role of executive VP, chief growth officer, for McCann Health North America. Ms. Fischer has more than two decades of healthcare expertise. She was president

of GSW Worldwide New York. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0416-Pool



► BIOPHARMA POOL

Dr. Leila Alland **TARVEDA THERAPEUTICS APPOINTS CHIEF MEDICAL OFFICER**

Tarveda Therapeutics has appointed Leila Alland, M.D., to the position of chief medical officer. Dr. Alland brings more than 15 years of pharmaceutical drug development experience with a focus on oncology including leadership roles in clinical development at AstraZeneca and Bristol-Myers Squibb.

Tarveda Therapeutics is a biopharmaceutical company discovering and developing Pentarins as a new class of targeted anti-cancer medicines.

Steve Hoerter **AGIOS APPOINTS CHIEF COMMERCIAL OFFICER**

Agios Pharmaceuticals, a leader in the fields of cancer metabolism and rare genetic metabolic disorders, has appointed Steve Hoerter to the newly created position of chief commercial officer. Mr. Hoerter most recently served as executive VP and chief commercial officer at Clovis Oncology.

Dr. Deborah Thomas **SUNESIS PHARMACEUTICALS ANNOUNCES PROMOTION**

Sunesis Pharmaceuticals has promoted Deborah Thomas, Ph.D., to the role of senior VP, regulatory affairs, quality assurance, and nonclinical development. Dr. Thomas joined Sunesis in November 2011 as executive director, regulatory affairs. She has more than 25 years of biotechnology and pharmaceutical industry experience.

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers.

► BIOTECH POOL

Dr. Steven Fischkoff **LION BIOTECHNOLOGIES NAMES CHIEF MEDICAL OFFICER**

Lion Biotechnologies, which is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), has appointed Steven Fischkoff, M.D., as chief medical officer (CMO).

With 25 years of biopharmaceutical experience, Dr. Fischkoff most recently served as VP of clinical and medical affairs at Celgene Cellular Therapeutics, where his responsibilities included the development of cell based products for the treatment of malignant and non-malignant diseases.

Craig Fraser **DISCOVERY LABS APPOINTS CEO**

Discovery Laboratories, a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, has appointed Craig Fraser president and CEO. Mr. Fraser succeeds John Cooper. Before joining Discovery Labs, Mr. Fraser held a number of leadership positions, most recently as chief operating officer at Aegerion Pharmaceuticals.

Dr. Gurdyal Kalsi **TISSUEGENE APPOINTS CHIEF MEDICAL OFFICER**

TissueGene, a regenerative medicine company using cell and gene therapy to develop novel regenerative drugs, has appointed Gurdyal Kalsi, M.D., to the role of chief medical officer, senior VP, clinical development and medical affairs. Dr. Kalsi oversees and directs the clinical development of TissueGene's novel injectable therapy for knee osteoarthritis called Invossa, a genetically modified allogeneic cell therapy that will soon be entering Phase III clinical trials in the United States.

Dr. Kalsi most recently served as corporate VP for clinical development and medical affairs at Emergent BioSolutions.

Kimberly Manhard **HERON THERAPEUTICS APPOINTS EXECUTIVE VP OF DRUG DEVELOPMENT**

Heron Therapeutics, a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, has appointed Kimberly Manhard executive VP of drug development.

Since 2008, Ms. Manhard has served as the senior VP of regulatory affairs and development operations at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca.

Dr. Vito Palombella **SURFACE ONCOLOGY APPOINTS CHIEF SCIENTIFIC OFFICER**

Surface Oncology, a leader in the development of next-generation cancer immunotherapies, has appointed Vito Palombella, Ph.D., as chief scientific officer. Dr. Palombella brings 20 years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations to this role.

Before joining Surface, Dr. Palombella was the executive VP and chief scientific officer at Infinity Pharmaceuticals, where he was responsible for drug discovery and preclinical development.

Dr. Michael Washabaugh **THERAPEUTIC PROTEINS APPOINTS CHIEF SCIENTIFIC OFFICER**

Therapeutic Proteins International (TPI) has appointed Michael Washabaugh, Ph.D. as its new chief scientific officer.

Dr. Washabaugh has more than 20 years of experience in therapeutic protein and vaccine development. Before joining TPI, he assumed a senior leadership R&D role at MedImmune, a subsidiary of AstraZeneca, primarily responsible for preclinical and late-stage clinical development of vaccine and biological candidates.

► SPECIALTY POOL

Michael Moran **EAGLE PHARMACEUTICALS APPOINTS U.S. HEAD OF SALES**

Eagle Pharmaceuticals has appointed Michael Moran to the role of U.S. head of sales. Before joining Eagle he spent seven years in various leadership roles at GlaxoSmithKline, including most recently the role of field VP. Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products.

Dr. Kalpana Patel **Christine Rosser** **SCILEX PHARMACEUTICALS BOOSTS MEDICAL AFFAIRS AND REGULATORY EXPERTISE**

Scilex Pharmaceuticals, a company engaged in the development and commercialization of products focused on the treatment of pain, has appointed medical and regulatory affairs executives, as the company advances in its assessment of several unique drug candidates.


The new hires include Dr. Kalpana Patel as senior director of medical affairs and Christine Rosser as senior director of regulatory affairs. Dr. Patel has more than 16 years of medical affairs experience, developing key projects for global companies such as Johnson & Johnson and Pfizer.

Ms. Rosser has more than 20 years of pharma regulatory expertise at global pharma companies, including Pfizer and Endo Pharmaceuticals.

► TECHNOLOGY POOL

William Febbo **OPTIMIZERX APPOINTS CEO**

OptimizeRx, a software company whose content-delivery platform enables pharmaceutical companies to provide on-demand patient-savings and support services right at point of prescribing, has appointed William Febbo as CEO. Mr. Febbo succeeds David Harrell, who will continue to serve as chairman of the board.

Mr. Febbo's career includes strategic development, technology and product innovation, corporate finance, and M&A within a variety of leadership roles. 

DIA 2016

JUNE 26-30 | PHILADELPHIA, PA

DIA 2016 is packed with 175+ educational offerings over 22 tracks on today's hottest topics. It is our largest interdisciplinary event, bringing together a global network of 7,000+ life sciences professionals from industry, academia, regulatory and government agencies, and patient and philanthropic organizations from around the globe, to foster innovation in the discovery, development, and life cycle management of health care products.



Just Announced - DIA 2016 Co-Chairs:

Hans-Georg Eichler, MD, MSc

Senior Medical Officer, European Medicines Agency



Gigi Hirsch, MD

Executive Director, MIT Center for Biomedical Innovation

Featured Sessions:

- Disease Interception: Shifting the Paradigm from Treatment to Prevention of Disease
- Expedited Reviews and Other Pathways to Speed up Access to Medicines
- Lessons Learned from Eight Years of Drug Development Tool/Novel Methodology Qualification
- Regulatory Science Considerations Applying to Novel Biologics and Bifunctional Biologics Development
- Infectious Disease Containment and Lessons Learned

Featured Highlights

- Global regulatory presence with representatives from FDA, EMA, PMDA, Health Canada, and more
- NEW Engage and Exchange Sessions: Engage with fellow attendees in a new, collaborative learning environment
- Increase your knowledge while allowing for small group interaction with DIA 2016 Preconference Tutorials
- Hear from the top thought-leaders in drug development discuss topics such as 21st Century Cures, biologics/biosimilars, patient engagement, mobile/wearable technology, big data, personalized medicine, approval pathways, pricing, reimbursement and access, plus much more

A GATHERING OF GLOBAL PROPORTIONS

Visit DIAGlobal.org/DIA2016 for more information and to register.



Agenda
Now
Available

#DIA2016

